全文获取类型
收费全文 | 1982篇 |
免费 | 130篇 |
国内免费 | 8篇 |
专业分类
耳鼻咽喉 | 23篇 |
儿科学 | 127篇 |
妇产科学 | 47篇 |
基础医学 | 214篇 |
口腔科学 | 77篇 |
临床医学 | 184篇 |
内科学 | 329篇 |
皮肤病学 | 54篇 |
神经病学 | 99篇 |
特种医学 | 70篇 |
外科学 | 349篇 |
综合类 | 21篇 |
一般理论 | 1篇 |
预防医学 | 97篇 |
眼科学 | 80篇 |
药学 | 207篇 |
中国医学 | 7篇 |
肿瘤学 | 134篇 |
出版年
2023年 | 39篇 |
2022年 | 74篇 |
2021年 | 126篇 |
2020年 | 45篇 |
2019年 | 58篇 |
2018年 | 80篇 |
2017年 | 50篇 |
2016年 | 68篇 |
2015年 | 62篇 |
2014年 | 81篇 |
2013年 | 100篇 |
2012年 | 143篇 |
2011年 | 112篇 |
2010年 | 62篇 |
2009年 | 53篇 |
2008年 | 88篇 |
2007年 | 74篇 |
2006年 | 71篇 |
2005年 | 74篇 |
2004年 | 60篇 |
2003年 | 53篇 |
2002年 | 62篇 |
2001年 | 46篇 |
2000年 | 41篇 |
1999年 | 39篇 |
1998年 | 17篇 |
1997年 | 18篇 |
1996年 | 12篇 |
1995年 | 5篇 |
1994年 | 12篇 |
1993年 | 11篇 |
1992年 | 29篇 |
1991年 | 24篇 |
1990年 | 23篇 |
1989年 | 18篇 |
1988年 | 27篇 |
1987年 | 14篇 |
1986年 | 20篇 |
1985年 | 16篇 |
1984年 | 11篇 |
1982年 | 10篇 |
1980年 | 8篇 |
1979年 | 8篇 |
1978年 | 8篇 |
1977年 | 6篇 |
1974年 | 11篇 |
1972年 | 7篇 |
1970年 | 5篇 |
1968年 | 4篇 |
1967年 | 4篇 |
排序方式: 共有2120条查询结果,搜索用时 203 毫秒
991.
992.
Hybrid-primed lymphocytes and hybrid vaccination prevent tumor growth of lewis lung carcinoma in mice 总被引:1,自引:0,他引:1
Savai R Schermuly RT Schneider M Pullamsetti SS Grimminger F Seeger W Banat GA 《Journal of immunotherapy (Hagerstown, Md. : 1997)》2006,29(2):175-187
Dendritic cell (DC)-tumor cell hybrids are currently being evaluated as a novel antitumor vaccination strategy. We have explored in an animal model whether administration of DCs fused with poorly immunogenic carcinoma cells could elicit an antitumor response. Fusion of C57/BL6 mice bone marrow-derived DCs with Lewis lung carcinoma (LLC1) cells resulted in approximately 50% fusion efficiency. Hybrid cells (HCs) were used to explore 3 potential tumor therapy strategies: protective immunization, vaccination, and adoptive cellular therapy. Immunization with HCs induced activation of proliferating cytotoxic T cells, upregulation of distinct cytokines genes, and a significant retardation of tumor growth. Similar results were observed by vaccination with HCs in the tumor-bearing host. Finally, when T cells from HC-vaccinated mice were transferred into naive tumor-bearing mice, tumor growth was strongly retarded and an efficient proliferative and cytotoxic T-cell response was observed. Tumor growth was reduced by more than 50%, and tumor development was significantly delayed. Taken together, we demonstrate that HCs offer effective immunotherapy of poorly immunogenic carcinomas. This is independent of whether the HCs are taken for adoptive transfer or as a vaccine. 相似文献
993.
Albert DH Tapang P Magoc TJ Pease LJ Reuter DR Wei RQ Li J Guo J Bousquet PF Ghoreishi-Haack NS Wang B Bukofzer GT Wang YC Stavropoulos JA Hartandi K Niquette AL Soni N Johnson EF McCall JO Bouska JJ Luo Y Donawho CK Dai Y Marcotte PA Glaser KB Michaelides MR Davidsen SK 《Molecular cancer therapeutics》2006,5(4):995-1006
ABT-869 is a structurally novel, receptor tyrosine kinase (RTK) inhibitor that is a potent inhibitor of members of the vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) receptor families (e.g., KDR IC50 = 4 nmol/L) but has much less activity (IC50s > 1 micromol/L) against unrelated RTKs, soluble tyrosine kinases, or serine/threonine kinases. The inhibition profile of ABT-869 is evident in cellular assays of RTK phosphorylation (IC50 = 2, 4, and 7 nmol/L for PDGFR-beta, KDR, and CSF-1R, respectively) and VEGF-stimulated proliferation (IC50 = 0.2 nmol/L for human endothelial cells). ABT-869 is not a general antiproliferative agent because, in most cancer cells, >1,000-fold higher concentrations of ABT-869 are required for inhibition of proliferation. However, ABT-869 exhibits potent antiproliferative and apoptotic effects on cancer cells whose proliferation is dependent on mutant kinases, such as FLT3. In vivo ABT-869 is effective orally in the mechanism-based murine models of VEGF-induced uterine edema (ED50 = 0.5 mg/kg) and corneal angiogenesis (>50% inhibition, 15 mg/kg). In tumor growth studies, ABT-869 exhibits efficacy in human fibrosarcoma and breast, colon, and small cell lung carcinoma xenograft models (ED50 = 1.5-5 mg/kg, twice daily) and is also effective (>50% inhibition) in orthotopic breast and glioma models. Reduction in tumor size and tumor regression was observed in epidermoid carcinoma and leukemia xenograft models, respectively. In combination, ABT-869 produced at least additive effects when given with cytotoxic therapies. Based on pharmacokinetic analysis from tumor growth studies, efficacy correlated more strongly with time over a threshold value (cellular KDR IC50 corrected for plasma protein binding = 0.08 microg/mL, >or=7 hours) than with plasma area under the curve or Cmax. These results support clinical assessment of ABT-869 as a therapeutic agent for cancer. 相似文献
994.
995.
996.
997.
N N Mahajan K N Mahajan R N Soni N L Gaikwad 《Ultrasound in obstetrics & gynecology》2007,29(4):479; author reply 479-479; author reply 480
998.
999.
1000.